Which one is better, pirfenidone or nintedanib?

Pirfenidone (Pirfenidone) and nintedanib (Nintedanib) are the most commonly used anti-fibrotic drugs for idiopathic pulmonary fibrosis (IPF). In real-life settings, both drugs were effective in reducing 24-month decline in forced vital capacity and diffuse vital capacity. The sicker patients in both groups were likely to show a more rapid decline in respiratory function.

The median survival time after diagnosis of idiopathic pulmonary fibrosis is 2-5 years. The main goal of treating idiopathic pulmonary fibrosis is to stabilize or reduce the rate of disease progression. The median age of patients receiving nintedanib was higher than that of the pirfenidone group (p<0.0001). The most common symptoms at onset were exertional dyspnea and dry cough, and there was no statistically significant difference between the two groups (p>0.05). All patients with IPF present with bibasilar clefts at diagnosis. There were no significant differences in FVC, FEV1, TLC, and DLCO between the pirfenidone and nitanni treatment groups after 0 or 6 months (p>0.05). After one year, pulmonary function test parameters remained stable relative to baseline in patients receiving pirfenidone.

Pirfenidone has been approved for marketing in China under the trade name of Asri. It has entered the scope of Class B medical insurance and is limited to patients with idiopathic pulmonary fibrosis. The specifications produced by domestic pharmaceutical factoriesThe price of 100mg*54 capsules per box is around RMB 500. There are also generic pirfenidone drugs produced in other countries overseas. For example, the price of a box of 200mg*30 tablets produced by an Indian pharmaceutical factory is around RMB 100 (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.